DEA to host listening sessions on telemedicine prescribing of controlled substances

Aug 04, 2023 - 04:02 PM
Maternal Health Case Study Engaging Mothers Through Technology UPMC Magee Image 900 x 400

The Drug Enforcement Administration will host public listening sessions Sept. 12-13 to receive additional input on whether to permit telemedicine prescribing for certain controlled substances without any in-person medical evaluation, and data or other safeguards to prevent and detect their diversion. Registration for in-person attendance and for organizations wishing to make oral presentations opens Monday. Oral presentations may be 
given in-person or by video teleconference. Registrations are due Aug. 21. DEA will also livestream the listening sessions online.

The DEA and the Substance Abuse and Mental Health Services Administration in May released a temporary rule extending telehealth prescribing flexibilities for buprenorphine and other controlled substances through Nov. 11, 2024, while they develop final regulations, as urged by the AHA. Among other changes, AHA has urged the DEA to establish a special registration process (as statutorily mandated) to waive the in-person evaluations for practitioners who register with the agency.

Related News Articles

Headline
AHA comments on CMS physician fee schedule proposed rule for CY 2026
The AHA commented Sept. 12 on the Centers for Medicare & Medicaid Services calendar year 2026 physician fee schedule proposed rule. The AHA applauded CMS…
Headline
FDA issues guidance to expand non-opioid treatments for chronic pain
The Food and Drug Administration Sept. 10 released draft guidance on non-opioid treatments for treating chronic pain and reducing prescription opioid misuse.…
Headline
Study finds less than 40% of Medicare beneficiaries with OUD receive standard care
A Health Affairs study published Sept. 2 found that less than 40% of Medicare beneficiaries with opioid use disorder received standard care in alignment with…
Headline
New CDC campaign addresses youth substance use, mental health
The Centers for Disease Control and Prevention Aug. 5 announced a new campaign educating youth ages 12-17 on substance use, mental health and how they are…
Headline
FDA announces labeling changes to opioid pain medications 
The Food and Drug Administration July 31 announced that it is requiring safety label changes to all opioid pain medications to further emphasize and explain…
Headline
Toolkit highlights care transitions for patients with OUD or StUD
The AHA released a new toolkit to improve continuity of care for patients with opioid and stimulant use disorders. Developed with support from the Centers for…